| MeSH term | MeSH ID | Detail |
|---|---|---|
| Conjunctivitis, Bacterial | D003234 | 3 associated lipids |
| Conjunctivitis, Inclusion | D003235 | 4 associated lipids |
| Corneal Opacity | D003318 | 3 associated lipids |
| Coronary Disease | D003327 | 70 associated lipids |
| Corynebacterium Infections | D003354 | 7 associated lipids |
| Crohn Disease | D003424 | 12 associated lipids |
| Cross Infection | D003428 | 9 associated lipids |
| Cryptosporidiosis | D003457 | 3 associated lipids |
| Cystic Fibrosis | D003550 | 65 associated lipids |
| Cytomegalovirus Infections | D003586 | 7 associated lipids |
Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Saint-Criq V et al. | Restoration of chloride efflux by azithromycin in airway epithelial cells of cystic fibrosis patients. | 2011 | Antimicrob. Agents Chemother. | pmid:21220528 |
| Peric M et al. | Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. | 2003 | Antimicrob. Agents Chemother. | pmid:12604536 |
| Solomon AW et al. | Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. | 2005 | Antimicrob. Agents Chemother. | pmid:16251338 |
| Nalca Y et al. | Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. | 2006 | Antimicrob. Agents Chemother. | pmid:16641435 |
| Asgrimsson V et al. | Novel effects of azithromycin on tight junction proteins in human airway epithelia. | 2006 | Antimicrob. Agents Chemother. | pmid:16641453 |
| Batt SL et al. | Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. | 2003 | Antimicrob. Agents Chemother. | pmid:12936971 |
| Henry DC et al. | Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. | 2003 | Antimicrob. Agents Chemother. | pmid:12936972 |
| Chave JP et al. | Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. | 1992 | Antimicrob. Agents Chemother. | pmid:1324635 |
| Derouin F et al. | Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. | 1992 | Antimicrob. Agents Chemother. | pmid:1324642 |
| Ohrt C et al. | Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. | 2002 | Antimicrob. Agents Chemother. | pmid:12121927 |
| Dubois J et al. | In vitro and intracellular activities of peptide deformylase inhibitor GSK1322322 against Legionella pneumophila isolates. | 2015 | Antimicrob. Agents Chemother. | pmid:25348534 |
| Goldstein EJ et al. | Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. | 1999 | Antimicrob. Agents Chemother. | pmid:10543769 |
| Watt G et al. | Azithromycin activities against Orientia tsutsugamushi strains isolated in cases of scrub typhus in Northern Thailand. | 1999 | Antimicrob. Agents Chemother. | pmid:10543774 |
| Pajukanta R et al. | In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans. | 1992 | Antimicrob. Agents Chemother. | pmid:1329617 |
| Pandori MW et al. | Detection of azithromycin resistance in Treponema pallidum by real-time PCR. | 2007 | Antimicrob. Agents Chemother. | pmid:17620374 |
| Moon JE et al. | Efficacy of macrolides and telithromycin against leptospirosis in a hamster model. | 2006 | Antimicrob. Agents Chemother. | pmid:16723556 |
| Ng LK et al. | Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. | 2002 | Antimicrob. Agents Chemother. | pmid:12183262 |
| Matsui H et al. | Azithromycin inhibits the formation of flagellar filaments without suppressing flagellin synthesis in Salmonella enterica serovar typhimurium. | 2005 | Antimicrob. Agents Chemother. | pmid:16048953 |
| Carannante A et al. | Changing antimicrobial resistance profiles among Neisseria gonorrhoeae isolates in Italy, 2003 to 2012. | 2014 | Antimicrob. Agents Chemother. | pmid:25070110 |
| Zhang Y et al. | Novel Detection Strategy To Rapidly Evaluate the Efficacy of Antichlamydial Agents. | 2017 | Antimicrob. Agents Chemother. | pmid:27855081 |
| Waites KB et al. | In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China. | 2017 | Antimicrob. Agents Chemother. | pmid:27855075 |
| Shimuta K et al. | Antimicrobial resistance and molecular typing of Neisseria gonorrhoeae isolates in Kyoto and Osaka, Japan, 2010 to 2012: intensified surveillance after identification of the first strain (H041) with high-level ceftriaxone resistance. | 2013 | Antimicrob. Agents Chemother. | pmid:23939890 |
| D'Ignazio J et al. | Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. | 2005 | Antimicrob. Agents Chemother. | pmid:16189077 |
| Tissi L et al. | In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G. | 1995 | Antimicrob. Agents Chemother. | pmid:8540695 |
| Jensen JS et al. | In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains. | 2014 | Antimicrob. Agents Chemother. | pmid:24637681 |
| Koirala KD et al. | Highly resistant Salmonella enterica serovar Typhi with a novel gyrA mutation raises questions about the long-term efficacy of older fluoroquinolones for treating typhoid fever. | 2012 | Antimicrob. Agents Chemother. | pmid:22371897 |
| Binet R et al. | Impact of azithromycin resistance mutations on the virulence and fitness of Chlamydia caviae in guinea pigs. | 2010 | Antimicrob. Agents Chemother. | pmid:20065052 |
| Bermudez LE et al. | Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. | 2001 | Antimicrob. Agents Chemother. | pmid:11120969 |
| Ohara T et al. | Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response. | 2002 | Antimicrob. Agents Chemother. | pmid:12384353 |
| Bielaszewska M et al. | Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. | 2012 | Antimicrob. Agents Chemother. | pmid:22391549 |
| Fuentes F et al. | Postanitbiotic and sub-MIC effects of azithromycin and isepamicin against Staphylococcus aureus and Escherichia coli. | 1998 | Antimicrob. Agents Chemother. | pmid:9527796 |
| Kashuba AD and Amsden GW | Bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9527816 |
| Nagai K et al. | Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes. | 2001 | Antimicrob. Agents Chemother. | pmid:11600391 |
| Cigana C et al. | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. | 2007 | Antimicrob. Agents Chemother. | pmid:17210769 |
| Nahata MC et al. | Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. | 1995 | Antimicrob. Agents Chemother. | pmid:7486938 |
| Tomazic J et al. | Ex vivo effect of azithromycin in human leukocyte bactericidal functions. | 1995 | Antimicrob. Agents Chemother. | pmid:7486947 |
| Ouyang-Latimer J et al. | In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008. | 2011 | Antimicrob. Agents Chemother. | pmid:21115800 |
| Nagai K et al. | Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries. | 2002 | Antimicrob. Agents Chemother. | pmid:11796375 |
| Vazifeh D et al. | Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin. | 1997 | Antimicrob. Agents Chemother. | pmid:9333032 |
| Sugimura M et al. | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. | 2008 | Antimicrob. Agents Chemother. | pmid:18676884 |
| Ramya TN et al. | Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum. | 2007 | Antimicrob. Agents Chemother. | pmid:17060533 |
| Su XH et al. | Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914). | 2015 | Antimicrob. Agents Chemother. | pmid:26482313 |
| Rakita RM et al. | Intracellular activity of azithromycin against bacterial enteric pathogens. | 1994 | Antimicrob. Agents Chemother. | pmid:7810998 |
| Ma Q et al. | A Waterborne Outbreak of Shigella sonnei with Resistance to Azithromycin and Third-Generation Cephalosporins in China in 2015. | 2017 | Antimicrob. Agents Chemother. | pmid:28373192 |
| Wind CM et al. | A Case-Control Study of Molecular Epidemiology in Relation to Azithromycin Resistance in Neisseria gonorrhoeae Isolates Collected in Amsterdam, the Netherlands, between 2008 and 2015. | 2017 | Antimicrob. Agents Chemother. | pmid:28373191 |
| Pérez-MartÃnez I and Haas D | Azithromycin inhibits expression of the GacA-dependent small RNAs RsmY and RsmZ in Pseudomonas aeruginosa. | 2011 | Antimicrob. Agents Chemother. | pmid:21537014 |
| Odenholt I et al. | Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase. | 1997 | Antimicrob. Agents Chemother. | pmid:9371360 |
| Welsh L et al. | In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. | 1996 | Antimicrob. Agents Chemother. | pmid:8787907 |
| Waites KB et al. | In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas. | 2015 | Antimicrob. Agents Chemother. | pmid:25824220 |
| Matzneller P et al. | Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. | 2013 | Antimicrob. Agents Chemother. | pmid:23357769 |